Editorial
The use of drugs beyond licence in palliative care and pain management
Earlier this year, a working party representing the Association for Palliative Medicine (APM) and The Pain Society produced a position statement setting out the views of both societies in relation to the use of drugs beyond their product licence in clinical practice. The working party included clinical, managerial, legal, and patient representatives. The position statement is an important first step in clarifying the legal position and recognizing -and dealing with -the potential risks that this practice poses to all involved. The statement is intended to make clear that this practice is necessary and legal, but at the same time stresses that efforts should be made to reduce any risks associated with this practice.
The Medicines Control Agency in the UK grants a licence (or marketing authorization) for a product for which therapeutic claims are made. The purpose of the licence is to regulate the activity of the pharmaceutical company when marketing the drug. The licence does not restrict the prescription of the drug by properly qualified medical practitioners. Licensed drugs can be used legally in clinical situations that fall outside the remit of the licence (referred to as 'off-label'), e.g., a different age group, a different indication, a different dose, or route, or method of administration. Use of unlicensed drugs refers to those products that have no licence for any clinical situation or may be in the process of evaluation leading to such a licence.
Off-label prescribing is common in palliative care, but use of unlicensed drugs is rare. A recent audit found that around a third of prescriptions affecting around 66% of patients in one specialist palliative care unit was offlabel. This is similar to paediatric clinical practice where audits in the UK and Europe have shown that 39-55% of prescriptions were off-label, and 7-10% of prescriptions were for unlicensed drugs.2 At least twothirds of children receive an off-label or unlicensed drug during an inpatient admission.
The main risk to patients when using off-label drugs relates to informed consent. The duty of care recommended by the General Medical Council and the medical defence organizations is that doctors provide information to patients on the nature and associated risks of any treatment, including off-label and unlicensed drugs, and that they record the outcome of these discussions. However, a survey of senior doctors working in palliative medicine revealed that 97% of respondents did not op-erate a policy in these circumstances, 93% did not limit prescribing to consultants in this way, and only 4% always obtained verbal consent when using offlabel drugs.3 Specific, written consent should always be sought for the use of unlicensed drugs or drugs used innovatively. But it is the view of the working party that seeking written consent is not practical in clinical circumstances where the use of off-label medications is routine, as may be the case in certain specialties.
The main concern of practitioners is that the use of unlicensed or off-label drugs could prompt legal action. A claim founded in negligence can only succeed if foreseeable injury has occurred as a consequence of breach of a duty of care. The standard expected of practitioners in the UK is primarily determined by the 'Bolam' principle (acting in accordance with a responsible body of medical opinion in that specialty), but current law requires that such opinion be logical and capable of withstanding critical questioning. A successful claim leads to an award of damages. Life expectancy and loss of earnings are incorporated in the calculation of damages; thus, high-value claims can easily arise from the management of chronic pain, but are most unlikely in palliative care.
It is now a requirement in the UK for medication to be dispensed with written information provided by the manufacturer. The information refers only to indications, doses, and routes of administration for which the drug has a licence. This can lead to poor concordance with medication regimens. Patients may become anxious, and less experienced health care professionals may be confused, by conflicting information given verbally by prescribers and in written form by pharmacists. A good example is the well-established use of anti-depressants or anti-epileptics for pain management, when pharmacists are compelled to give patients the information leaflet about the licensed indications, namely depression and epilepsy. The APM and The Pain Society believe that there is a need to design accurate information for patients and their carers about the use of drugs beyond licence and are seeking support in this endeavour.
From an organizational perspective, the risks presented by staff (doctors, nurses, and pharmacists) in using drugs beyond licence are best managed through a culture of clinical governance. This will be increasingly important as nurses become supplementary prescribers under recent Department of Health guidance. Clinical errors should be managed by establishing procedures that reduce the chance of that error being repeated and the National Patients Safety Agency encompasses this philosophy. Clinical governance should be viewed as a process for creating improved clinical outcomes and not used as a barrier to informed and risk-managed practice.
Future projects for the joint working party include the dissemination of the position statement to a large number of UK health care agencies. Comment will be invited, but the group is particularly keen to know whether these organizations are prepared to support the developments suggested. The statement will also be distributed to NHS Trusts and other professional groups such as those representing nurses and pharmacists. Staff and patient information leaflets that will be available from both societies' web sites will be produced. Perhaps the greatest task is to continue to review and raise awareness of the evidence, or lack of it, in areas of clinical practice where drugs are used beyond their licence.4 It is hoped that this will lead to collaboration with industry with the object of extending licences based on currently available data or embarking on research projects to answer clinical questions about the use of drugs beyond licence. This could prove to be a useful starting point for the National Cancer Research Institute clinical studies group representing palliative care. 6) Health professionals involved in prescribing, dispensing, and administering drugs beyond licence should select those drugs that offer the best balance of benefit against harm for any given patient. 7) Health professionals should inform, change, and monitor their practice with regard to drugs used beyond licence in the light of evidence from audit and published research. 8) The Department of Health should work with health professionals and the pharmaceutical industry to enable and encourage the extension of product licences where there is evidence of benefit in circumstances of defined clinical need. 9) Organizations providing palliative care and pain management services should support therapeutic practices that are underpinned by evidence and advocated by a responsible body of professional opinion.
